Prometheus Bio is ready for its close-up shot, following a $130M round to back IBD drugs now headed to the clinic
A little over a year ago, Takeda lined up a deal to collaborate with a low-profile San Diego upstart called Prometheus Biosciences on a string of new drugs for inflammatory bowel disease. The pharma player tossed an undisclosed upfront and up to $420 million in milestones to get the alliance started.
These days, preclinical deals are common, milestones are hazy markers of financial health and the pact didn’t get a lot of attention. But that obscurity should start to dissipate this week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.